Advances in urinary biomarker discovery in urological research

被引:22
作者
Kim, Jayoung [1 ,2 ,3 ]
Kim, Won Tae [4 ,5 ]
Kim, Wun-Jae [4 ,5 ]
机构
[1] Cedars Sinai Med Ctr, Dept Surg, Los Angeles, CA 90048 USA
[2] Cedars Sinai Med Ctr, Dept Biomed Sci, Los Angeles, CA 90048 USA
[3] Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90024 USA
[4] Chungbuk Natl Univ, Dept Urol, Coll Med, 1 Chungdae Ro, Cheongju 28644, South Korea
[5] Chungbuk Natl Univ Hosp, Dept Urol, Cheongju, South Korea
基金
新加坡国家研究基金会; 美国国家卫生研究院;
关键词
Biomarkers; Cystitis; interstitial; Urinary bladder; Urinary bladder neoplasms; Urine; TRANSITIONAL-CELL CARCINOMA; IN-SITU HYBRIDIZATION; UROTHELIAL CANCER BIOMARKERS; PIK3CA GENE ALTERATIONS; BLADDER-CANCER; DNA METHYLATION; SYNDROME/INTERSTITIAL CYSTITIS; INTERSTITIAL CYSTITIS; EPIGENETIC BIOMARKERS; MULTIPLE GENES;
D O I
10.4111/icu.2020.61.S1.S8
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
A disease-specific biomarker (or biomarkers) is a characteristic reflecting a pathological condition in human body, which can be used as a diagnostic or prognostic tool for the clinical management. A urine-based biomarker(s) may provide a clinical value as attractive tools for clinicians to utilize in the clinical setting in particular to bladder diseases including bladder cancer and other bladder benign dysfunctions. Urine can be easily obtained by patients with no preparation or painful procedures required from patients' side. Currently advanced omits technologies and computational power identified potential omits-based novel biomarkers. An unbiased profiling based on transcriptomics, proteomics, epigenetics, metabolomics approaches et al. found that expression at RNA, protein, and metabolite levels are linked with specific bladder diseases and outcomes. In this review, we will discuss about the urine-based biomarkers reported by many investigators including us and how these biomarkers can be applied as a diagnostic and prognostic tool in clinical trials and patient care to promote bladder health. Furthermore, we will discuss how these promising biomarkers can be developed into a smart medical device and what we should be cautious about toward being used in real clinical setting.
引用
收藏
页码:S8 / S22
页数:15
相关论文
共 100 条
[1]  
Abrams P, 2002, NEUROUROL URODYNAM, V21, P167, DOI 10.1002/nau.10052
[2]  
[Anonymous], UROL ONCOL
[3]   The role of STAG2 in bladder cancer [J].
Aquila, Lanni ;
Ohm, Joyce ;
Woloszynska-Read, Anna .
PHARMACOLOGICAL RESEARCH, 2018, 131 :143-149
[4]   Recurrent inactivation of STAG2 in bladder cancer is not associated with aneuploidy [J].
Balbas-Martinez, Cristina ;
Sagrera, Ana ;
Carrillo-de-Santa-Pau, Enrique ;
Earl, Julie ;
Marquez, Mirari ;
Vazquez, Miguel ;
Lapi, Eleonora ;
Castro-Giner, Francesc ;
Beltran, Sergi ;
Bayes, Monica ;
Carrato, Alfredo ;
Cigudosa, Juan C. ;
Dominguez, Orlando ;
Gut, Marta ;
Herranz, Jesus ;
Juanpere, Nuria ;
Kogevinas, Manolis ;
Langa, Xavier ;
Lopez-Knowles, Elena ;
Lorente, Jose A. ;
Lloreta, Josep ;
Pisano, David G. ;
Richart, Laia ;
Rico, Daniel ;
Salgado, Rocio N. ;
Tardon, Adonina ;
Chanock, Stephen ;
Heath, Simon ;
Valencia, Alfonso ;
Losada, Ana ;
Gut, Ivo ;
Malats, Nuria ;
Real, Francisco X. .
NATURE GENETICS, 2013, 45 (12) :1464-U221
[5]   Prevalence of Symptoms of Bladder Pain Syndrome/Interstitial Cystitis Among Adult Females in the United States [J].
Berry, Sandra H. ;
Elliott, Marc N. ;
Suttorp, Marika ;
Bogart, Laura M. ;
Stoto, Michael A. ;
Eggers, Paul ;
Nyberg, Leroy ;
Clemens, J. Quentin .
JOURNAL OF UROLOGY, 2011, 186 (02) :540-544
[6]   Alterations of DNA methylome in human bladder cancer [J].
Besaratinia, Ahmad ;
Cockburn, Myles ;
Tommasi, Stella .
EPIGENETICS, 2013, 8 (10) :1013-1022
[7]   FGFR3, TERT and OTX1 as a Urinary Biomarker Combination for Surveillance of Patients with Bladder Cancer in a Large Prospective Multicenter Study [J].
Beukers, Willemien ;
van der Keur, Kirstin A. ;
Kandimalla, Raju ;
Vergouwe, Yvonne ;
Steyerberg, Ewout W. ;
Boormans, Joost L. ;
Jensen, Jorgen B. ;
Lorente, Jose A. ;
Real, Francisco X. ;
Segersten, Ulrike ;
Orntoft, Torben F. ;
Malats, Nuria ;
Malmstrom, Per-Uno ;
Dyrskjot, Lars ;
Zwarthoff, Ellen C. .
JOURNAL OF UROLOGY, 2017, 197 (06) :1410-1417
[8]   HRAS mutations in bladder cancer at an early age and the possible association with the Costello Syndrome [J].
Beukers, Willemien ;
Hercegovac, Aleksander ;
Zwarthoff, Ellen C. .
EUROPEAN JOURNAL OF HUMAN GENETICS, 2014, 22 (06) :837-839
[9]   Quantitative molecular urinary cytology by fluorescence in situ hybridization:: a tool for tailoring surveillance of patients wit superficial bladder cancer? [J].
Bollmann, V ;
Heller, H ;
Bánkfalvi, A ;
Griefingholt, H ;
Bollmann, R .
BJU INTERNATIONAL, 2005, 95 (09) :1219-1225
[10]   Bradeion (SEPT4) as a Urinary Marker of Transitional Cell Bladder Cancer: A Real-Time Polymerase Chain Reaction Study of Gene Expression [J].
Bongiovanni, Luca ;
Pirozzi, Filomena ;
Guidi, Francesco ;
Orsini, Massimiliano ;
Chiurazzi, Pietro ;
Bassi, Pier Francesco ;
Racioppi, Marco .
JOURNAL OF UROLOGY, 2012, 187 (06) :2223-2227